#USA #New York #Class Action #Gross Law Firm #Nektar Therapeutics

Reminder for Nektar Therapeutics Shareholders

The Gross Law Firm has recently issued an important reminder to the shareholders of Nektar Therapeutics (NASDAQ: NKTR) regarding a significant deadline pertinent to a class-action lawsuit. Investors who acquired shares within the stipulated period are urged to reach out to the firm to discuss the possibility of being appointed a lead plaintiff. It is crucial to note that while this appointment is optional, participation in the recovery does not require it.

Important Details to Note

The class period for this lawsuit spans from February 26, 2025, to December 15, 2025. Shareholders who bought NKTR during this timeframe may have potential claims against the company based on misleading statements and pertinent omissions presented by the defendants throughout the class period. The allegations specify that crucial details regarding the REZOLVE-AA trial were not properly disclosed, which could have led to a significant negative impact on the trial's outcomes.

Allegations of Misleading Statements

The allegations against Nektar Therapeutics include:
1. Non-Compliance with Trial Protocols: The enrollment in the REZOLVE-AA trial was not conducted according to the necessary guidelines, raising doubts about the integrity of the trial.
2. Overstated Prospects: The overarching claims made by the company regarding the trial's potential success, based on the misleading enrollment claims, were thought to be exaggerated.
3. Material Misrepresentation: The public statements made by the defendants were misleading and failed to provide accurate information regarding the trial's conditions and results.

With these allegations, the Gross Law Firm emphasizes the importance for shareholders to act promptly as the deadline to seek lead plaintiff status is set for May 5, 2026.

Next Steps for Interested Shareholders

To participate in this class action, it is vital for shareholders to register quickly via the link provided by the Gross Law Firm. Once registered, shareholders will gain access to a monitoring system that will keep them updated on the case’s progress throughout its lifecycle.

Additionally, by registering their information, shareholders can ensure they receive timely notifications regarding any developments in the lawsuit. Importantly, there is no financial burden or obligation tied to participating in this action.

The Role of the Gross Law Firm

The Gross Law Firm stands out as a nationally recognized class action legal entity dedicated to protecting the rights of investors. Their mission is to advocate for those who have been misled or wronged by fraudulent practices in the investment ecosystem. Their commitment to corporate accountability resonates through their efforts to bring companies that engage in such practices to justice. Previous outcomes from similar cases bolster the firm's reputation, though, as stated, past results cannot assure future successes.

Contact Information for Further Inquiries

Shareholders looking to retrieve more information or who have questions regarding their eligibility can conveniently reach out to the Gross Law Firm:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

For those affected, this is a pivotal moment to ensure rights are upheld and potential recoveries pursued as part of this significant class-action lawsuit against Nektar Therapeutics.